The met receptor tyrosine kinase and basal breast cancer.

Park M

首页> 外文期刊>Cell cycle >The met receptor tyrosine kinase and basal breast cancer.

【24h】

The met receptor tyrosine kinase and basal breast cancer.

机译：Met受体酪氨酸激酶和基础乳腺癌。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Breast cancer is a complex disease that comprises cancers of distinct biologies and responses to treatment. Clinical management relies on traditional clinicopathological parameters, involving lymph node status, histological grade, as well as expression of the estrogen receptor or human epidermal growth factor receptor 2. Molecular pathology as well as protein and gene expression profiling have divided breast tumors into molecular subtypes associated with different clinical outcomes. One of these, defined as basal breast cancer, is associated with poor prognosis. Molecular mechanisms involved in the induction of basal breast cancer are poorly understood and targeted therapies for this subtype are lacking. Recent evidence using murine models identified a role for the Met receptor tyrosine kinase in the induction of murine mammary tumors with characteristics of human basal breast cancers. Moreover, elevated Met protein and RNA is associated with human basal tumors and poor outcome. These studies identify a link between the Met receptor tyrosine kinase, epithelial mesenchymal transition, and basal breast cancer. In this review, we provide an overview of murine Met models in relation to the spectrum of mouse models of breast cancer and a role for the Met receptor in basal breast cancer tumorigenesis.

机译：乳腺癌是一种复杂的疾病，包括癌症不同的生物学和治疗的反应。临床管理依赖于传统的临床病理学参数，涉及淋巴结状态，组织学等级以及雌激素受体或人表皮生长因子受体的表达。分子病理以及蛋白质和基因表达分析已经将乳腺肿瘤分成了相关的分子亚型具有不同的临床结果。其中一个定义为基础乳腺癌，与预后差有关。涉及基础乳腺癌的诱导的分子机制很差，并且缺乏该亚型的靶向疗法。最近使用鼠模型的证据确定了Met受体酪氨酸激酶在诱导人体基础乳腺癌特征的鼠乳腺癌中的作用。此外，升高的Met蛋白和RNA与人类基础肿瘤和差的结果有关。这些研究鉴定了MAT受体酪氨酸激酶，上皮间充质转变和基础乳腺癌之间的联系。在本次审查中，我们概述了与乳腺癌的小鼠模型的谱和基础乳腺癌肿瘤瘤中的MET受体的角色相关的鼠标符合Met Model的概述。

著录项

来源
《Cell cycle》 |2010年第6期|共8页
作者
Park M;
展开▼
作者单位

Rosalind and Morris Goodman Cancer Centre and Department of Experimental Medicine McGill University Montreal Quebec Canada.;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类细胞生物学;
关键词

相似文献

外文文献
中文文献
专利

1. The met receptor tyrosine kinase and basal breast cancer. [J] . Park M Cell cycle . 2010,第6期

机译：遇见受体酪氨酸激酶与基础乳腺癌。
2. The met receptor tyrosine kinase and basal breast cancer. [J] . Park M Cell cycle . 2010,第6期

机译：Met受体酪氨酸激酶和基础乳腺癌。
3. Estrogen receptor and receptor tyrosine kinase signaling: use of combinatorial hormone and epidermal growth factor receptor/human epidermal growth factor receptor 2-targeted therapies for breast cancer. [J] . Daniel J Zabransky, Ben Ho Park Journal of Clinical Oncology . 2014,第10期

机译：雌激素受体和酪氨酸激酶受体信号传导：组合激素和表皮生长因子受体/人表皮生长因子受体2靶向治疗乳腺癌的用途。
4. MRM-Based Global Kinome Profiling of Methylglyoxal-Induced Receptor Tyrosine Kinases Perturbation [C] . Weili Miao, Lei Guo, Yongsheng Xiao, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：基于MRM的全局Kinome甲基甘油诱导的受体酪氨酸激酶扰动
5. Overexpression of the receptor tyrosine kinase EphA2 induces malignant transformation of benign mammary epithelia: Implication for increased cell survival and altered cellular adhesions in breast cancer. [D] . Zelinski, Daniel Paul. 2001

机译：受体酪氨酸激酶EphA2的过表达诱导了良性乳腺上皮的恶性转化：暗示增加细胞存活率和改变乳腺癌细胞粘附。
6. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer [O] . Fatimah Matalkah, Elisha Martin, Hua Zhao, 2016

机译：SHP2在多种受体酪氨酸激酶的上游和下游均起作用以促进基底样和三阴性乳腺癌
7. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer. [O] . Sara Jansson, Pär-Ola Bendahl, Dorthe Aamand Grabau, 2014

机译：在4q12处紧密间隔的三种受体酪氨酸激酶c-KIT，VEGFR2和pDGFRα在三阴性乳腺癌中显示增加的蛋白质表达。

The met receptor tyrosine kinase and basal breast cancer.

摘要

著录项

相似文献

相关主题

期刊订阅